MT Newswires
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss
➖
AI Sentiment
Neutral
5/10
- Home
- CRBP
as of 12-12-2025 3:59pm EST
$9.69
+$0.05
+0.52%
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Chart Type:
Time Range:
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NORWOOD |
| Market Cap: | 202.6M | IPO Year: | N/A |
| Target Price: | $50.29 | AVG Volume (30 days): | 513.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.64 - $20.56 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 100.00% |
AI-Powered CRBP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 79.47%
79.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Corbus Pharmaceuticals Holdings Inc. (CRBP)
Cohen Yuval
Sell
Chief Executive Officer
CRBP Oct 27, 2025
Avg Cost/Share
$17.14
Shares
8,973
Total Value
$153,797.22
Owned After
138,187
SEC Form 4
Moran Sean F.
Sell
Chief Financial Officer
CRBP Oct 24, 2025
Avg Cost/Share
$17.02
Shares
12,981
Total Value
$220,936.62
Owned After
73,313
SEC Form 4
Cohen Yuval
Sell
Chief Executive Officer
CRBP Oct 24, 2025
Avg Cost/Share
$17.01
Shares
18,660
Total Value
$317,406.60
Owned After
138,187
SEC Form 4
Altmeyer Anne
Sell
Director
CRBP Oct 20, 2025
Avg Cost/Share
$20.50
Shares
1,060
Total Value
$21,730.00
Owned After
6,191
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Yuval | CRBP | Chief Executive Officer | Oct 27, 2025 | Sell | $17.14 | 8,973 | $153,797.22 | 138,187 | |
| Moran Sean F. | CRBP | Chief Financial Officer | Oct 24, 2025 | Sell | $17.02 | 12,981 | $220,936.62 | 73,313 | |
| Cohen Yuval | CRBP | Chief Executive Officer | Oct 24, 2025 | Sell | $17.01 | 18,660 | $317,406.60 | 138,187 | |
| Altmeyer Anne | CRBP | Director | Oct 20, 2025 | Sell | $20.50 | 1,060 | $21,730.00 | 6,191 |
Latest Corbus Pharmaceuticals Holdings Inc. News
CRBP Breaking Stock News: Dive into CRBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
📊
AI Sentiment
Positive
7/10
Compare CRBP vs Leading Stocks
See how CRBP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CRBP Corbus Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.